Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia

Author:

Tran Thai Hoa12ORCID,Harris Marian H.3,Nguyen Jonathan V.2,Blonquist Traci M.4ORCID,Stevenson Kristen E.4,Stonerock Eileen5,Asselin Barbara L.6,Athale Uma H.7ORCID,Clavell Luis A.8ORCID,Cole Peter D.9,Kelly Kara M.10ORCID,Laverdiere Caroline1ORCID,Leclerc Jean-Marie1,Michon Bruno11ORCID,Schorin Marshall A.12ORCID,Welch Jennifer J. G.13ORCID,Reshmi Shalini C.5ORCID,Neuberg Donna S.4ORCID,Sallan Stephen E.14,Loh Mignon L.2ORCID,Silverman Lewis B.14

Affiliation:

1. Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, QC, Canada;

2. Helen Diller Family Cancer Research Center, Department of Pediatrics, Benioff Children’s Hospital, University of California, San Francisco, San Francisco, CA;

3. Department of Pathology, Boston Children’s Hospital, Boston, MA;

4. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;

5. Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH;

6. Department of Pediatrics, University of Rochester School of Medicine and Wilmot Cancer Institute, Rochester, NY;

7. Division of Hematology/Oncology, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada;

8. San Jorge Children's Hospital, San Juan, Puerto Rico;

9. Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY;

10. Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY;

11. Département de Pédiatrie, Centre Mère-Enfant Soleil, Centre Hospitalier Universitaire de l’Université Laval, Québec City, QC, Canada;

12. Inova Fairfax Hospital for Children, Falls Church, VA;

13. Division of Pediatric Hematology/Oncology, Hasbro Children's Hospital/Brown University, Providence, RI; and

14. Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

Abstract

Key Points Fifteen percent of NCI high-risk, Ph-negative, B-ALL patients harbored a kinase-activating fusion, and often associated with IKZF1 deletion. IKZF1 deletion represents an independent prognostic factor of poor outcomes, regardless of fusion-positivity.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3